Zealand Pharma Preps Pipeline For Catalyst-Filled 2020
Biotech’s CEO Hopes For Four US approvals In 2020
Zealand Pharma’s recently installed CEO says it is building US operations to prepare for four potential approvals there in 2020, with commercial launches starting in 2021, its first ever.
You may also be interested in...
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.